. 1999 Aug;37(8):2639–2647. doi: 10.1128/jcm.37.8.2639-2647.1999

TABLE 8.

Determination of the specificity of Elecsys HBsAg and Auszyme Monoclonal B assays

Sample type or source or condition of sample donor^a	No. of samples tested	No. of samples with result^b:				Agreement (%)
Sample type or source or condition of sample donor^a	No. of samples tested	+/+	+/−	−/+	−/−	Agreement (%)
Autoimmune disease	35	0	0	0	35	100
Rheumatoid factor positive	40	3	0	0	37	100
Nonviral hepatitis liver disease	40	0	0	0	40	100
Anti-HCV positive	20	0	1	0	19	95
Anti-HAV positive	10	0	0	0	10	100
Anti-HEV positive	7	0	0	0	7	100
Rubella virus IgG positive	10	0	0	0	10	100
HSV IgG positive	19	0	0	0	19	100
EBV VCA IgG positive	10	0	0	0	10	100
Anti-CMV positive	10	0	0	0	10	100
Anti-Toxoplasma gondii positive	10	0	0	0	10	100
Treponema pallidum positive	22	0	0	0	22	100
Serum samples from HBV-vaccinated individuals	20	0	0	0	20	100
Dialysis patients	182	2	0	0	180	100
Hemophiliacs	20	0	0	0	20	100

HAV, hepatitis A virus; HEV, hepatitis E virus; HSV, herpes simplex virus; EBV VCA, Epstein-Barr virus capsid antigen; CMV, cytomegalovirus.

Symbols indicate result obtained with the Elecsys HBsAg assay/result obtained with the Auszyme Monoclonal B assay. +, positive result; −, negative result.